PABLO
ROJO CONEJO
Profesor titular de universidad
University of KwaZulu-Natal
Durban, SudáfricaUniversity of KwaZulu-Natal-ko ikertzaileekin lankidetzan egindako argitalpenak (13)
2024
2023
-
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial
The Lancet Child and Adolescent Health, Vol. 7, Núm. 10, pp. 718-727
2022
-
Advancing the prevention and treatment of HIV in children: priorities for research and development
The lancet. HIV, Vol. 9, Núm. 9, pp. e658-e666
-
Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial
BMC Medical Research Methodology, Vol. 22, Núm. 1
-
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
The Lancet HIV, Vol. 9, Núm. 9, pp. e627-e637
-
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial
The Lancet HIV, Vol. 9, Núm. 9, pp. e638-e648
-
What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studies
The Lancet HIV, Vol. 9, Núm. 9, pp. e649-e657
2021
-
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
New England Journal of Medicine, Vol. 385, Núm. 27, pp. 2531-2543
2019
-
Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list
The Lancet HIV, Vol. 6, Núm. 9, pp. e623-e631
2018
-
Early and highly suppressive antiretroviral therapy are main factors associated with low viral reservoir in European perinatally HIV-infected children
Journal of Acquired Immune Deficiency Syndromes
-
Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation
Journal of the International AIDS Society, Vol. 21, Núm. 11
2016
-
Kaposi sarcoma risk in HIV-infected children and adolescents on combination antiretroviral therapy from sub-Saharan Africa, Europe, and Asia
Clinical Infectious Diseases, Vol. 63, Núm. 9, pp. 1245-1253